ATE530187T1 - Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern - Google Patents
Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockernInfo
- Publication number
- ATE530187T1 ATE530187T1 AT08708026T AT08708026T ATE530187T1 AT E530187 T1 ATE530187 T1 AT E530187T1 AT 08708026 T AT08708026 T AT 08708026T AT 08708026 T AT08708026 T AT 08708026T AT E530187 T1 ATE530187 T1 AT E530187T1
- Authority
- AT
- Austria
- Prior art keywords
- 3alkyl
- ring
- 6alkyl
- nitrogen
- sodium channel
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 haloC1-3alkyl Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940125794 sodium channel blocker Drugs 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0701366.7A GB0701366D0 (en) | 2007-01-24 | 2007-01-24 | Novel pharmaceutical compositions |
| PCT/EP2008/050622 WO2008090115A1 (en) | 2007-01-24 | 2008-01-21 | Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530187T1 true ATE530187T1 (de) | 2011-11-15 |
Family
ID=37872717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08708026T ATE530187T1 (de) | 2007-01-24 | 2008-01-21 | Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090326032A1 (de) |
| EP (1) | EP2117562B1 (de) |
| JP (1) | JP2010516732A (de) |
| KR (1) | KR20090102867A (de) |
| CN (1) | CN101641102A (de) |
| AT (1) | ATE530187T1 (de) |
| AU (1) | AU2008208918A1 (de) |
| BR (1) | BRPI0807968A2 (de) |
| CA (1) | CA2676172A1 (de) |
| EA (1) | EA200970704A1 (de) |
| GB (1) | GB0701366D0 (de) |
| MX (1) | MX2009007915A (de) |
| TW (1) | TW200940509A (de) |
| WO (1) | WO2008090115A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (de) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamidderivate als natriumkanalmodulatoren |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| SG11201607332UA (en) | 2014-03-07 | 2016-10-28 | Hoffmann La Roche | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| PL3270915T3 (pl) | 2015-03-16 | 2020-08-24 | F. Hoffmann-La Roche Ag | Leczenie skojarzone z zastosowaniem agonisty tlr7 i inhibitora składania kapsydu hbv |
| EP3512556B1 (de) | 2016-09-13 | 2021-08-18 | F. Hoffmann-La Roche AG | Kombinierte behandlung mit einem tlr7-agonisten und einem hbv-capsid-anordnungsinhibitor |
| US11192856B2 (en) | 2017-10-05 | 2021-12-07 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| SG11202002707VA (en) | 2017-10-10 | 2020-04-29 | Biogen Inc | Process for preparing spiro derivatives |
| AU2020249331A1 (en) | 2019-03-25 | 2021-09-23 | F. Hoffmann-La Roche Ag | Solid forms of a compound of HBV core protein allosteric modifier |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| TW200728258A (en) * | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (de) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamidderivate als natriumkanalmodulatoren |
-
2007
- 2007-01-24 GB GBGB0701366.7A patent/GB0701366D0/en not_active Ceased
-
2008
- 2008-01-21 AT AT08708026T patent/ATE530187T1/de not_active IP Right Cessation
- 2008-01-21 CN CN200880009777A patent/CN101641102A/zh active Pending
- 2008-01-21 JP JP2009546729A patent/JP2010516732A/ja active Pending
- 2008-01-21 MX MX2009007915A patent/MX2009007915A/es unknown
- 2008-01-21 WO PCT/EP2008/050622 patent/WO2008090115A1/en active Application Filing
- 2008-01-21 BR BRPI0807968-4A2A patent/BRPI0807968A2/pt not_active IP Right Cessation
- 2008-01-21 KR KR1020097017502A patent/KR20090102867A/ko not_active Application Discontinuation
- 2008-01-21 CA CA002676172A patent/CA2676172A1/en not_active Abandoned
- 2008-01-21 EP EP08708026A patent/EP2117562B1/de not_active Not-in-force
- 2008-01-21 EA EA200970704A patent/EA200970704A1/ru unknown
- 2008-01-21 AU AU2008208918A patent/AU2008208918A1/en not_active Abandoned
- 2008-01-21 US US12/524,429 patent/US20090326032A1/en not_active Abandoned
-
2009
- 2009-02-20 TW TW098105547A patent/TW200940509A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2676172A1 (en) | 2008-07-31 |
| US20090326032A1 (en) | 2009-12-31 |
| EP2117562B1 (de) | 2011-10-26 |
| EA200970704A1 (ru) | 2010-02-26 |
| WO2008090115A1 (en) | 2008-07-31 |
| CN101641102A (zh) | 2010-02-03 |
| TW200940509A (en) | 2009-10-01 |
| JP2010516732A (ja) | 2010-05-20 |
| KR20090102867A (ko) | 2009-09-30 |
| MX2009007915A (es) | 2009-07-31 |
| EP2117562A1 (de) | 2009-11-18 |
| GB0701366D0 (en) | 2007-03-07 |
| BRPI0807968A2 (pt) | 2014-06-10 |
| AU2008208918A1 (en) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE530187T1 (de) | Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| DE602006009773D1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| DK1786790T3 (da) | Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EA200700099A1 (ru) | Производные пиридина | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
| EP1361220A4 (de) | Cyclische verbindungen mit thrombopoietinrezeporagonismus | |
| NO331174B1 (no) | Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister | |
| NO20091741L (no) | Pyrazolinforbindelser som mineralkortikoidreceptorantagonister | |
| EA200970706A1 (ru) | Новые фармацевтические композиции | |
| MX2018006225A (es) | Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
| ATE447575T1 (de) | Selektive spirocyclische glucocorticoid-rezeptor- modulatoren | |
| PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
| ATE455095T1 (de) | Vanilloidrezeptor trpv1-antagonisten | |
| EA201071259A1 (ru) | Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина | |
| CY1107890T1 (el) | Υποκατεστημενα παραγωγα 1-πιπεριδιν-3-υλ-4-πιπεριδιν-4-υλ-πιπεραζινης και χρηση τους ως ανταγωνιστων της νευροκινινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |